Ibrutinib-associated hemophagocytic lymphohistiocytosis: A case series from Johns Hopkins

Am J Hematol. 2019 Nov;94(11):E296-E299. doi: 10.1002/ajh.25611. Epub 2019 Aug 22.

Authors

Alexander J Ambinder¹, Bryan Hambley¹, Satish Shanbhag¹, Samuel A Merrill^{1

2}

Affiliations

¹ Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
² West Virginia University Cancer Institute, West Virginia University School of Medicine, Morgantown, West Virginia.

PMID: 31400009
DOI: 10.1002/ajh.25611

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't
Review

MeSH terms

Adenine / analogs & derivatives
Aged
Antineoplastic Agents / adverse effects*
Antineoplastic Agents / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Female
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / complications
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
Lymphohistiocytosis, Hemophagocytic / blood
Lymphohistiocytosis, Hemophagocytic / chemically induced*
Male
Middle Aged
Piperidines
Pyrazoles / adverse effects*
Pyrazoles / therapeutic use
Pyrimidines / adverse effects*
Pyrimidines / therapeutic use
Salvage Therapy
Waldenstrom Macroglobulinemia / complications
Waldenstrom Macroglobulinemia / drug therapy

Substances

Antineoplastic Agents
Piperidines
Pyrazoles
Pyrimidines
ibrutinib
Adenine